Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 4 institutions in 3 countries.
Muhammad Assad AslamDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-1905-2583
Mir Farshid AlemdehyDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0002-7936-0652
Bingtao HaoDepartment of Pathology, New York University School of Medicine, New York, NY 10016.ORCID 0000-0003-1997-9338
Peter H L KrijgerHubrecht Institute-Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center Utrecht, 3584 CT Utrecht, The Netherlands.
Colin E J PritchardMouse Clinic for Cancer and Aging Transgenic Facility, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Iris de RinkGenome Core Facility, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Fitriari Izzatunnisa MuhaiminDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Ika NurzijahDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Martijn van BaalenFlow Cytometry Facility, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-4058-4760
Ron M KerkhovenGenome Core Facility, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0003-1613-134X
Paul C M van den BerkDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
Jane A SkokDepartment of Pathology, New York University School of Medicine, New York, NY 10016.ORCID 0000-0002-4145-1516
Heinz JacobsDivision of Tumor Biology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; h.jacobs@nki.nl.ORCID 0000-0001-6227-9850
The Netherlands Cancer Institute · NLNew York University · USBahauddin Zakariya University · PKRoyal Netherlands Academy of Arts and Sciences · NL
Funding
Nuclear organization and its role in gene regulationR35GM122515 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2017 to 2026
$7.1M
NIGMS NIH HHS R35 GM122515
6 · The paper itself
Abstract
Development of progenitor B cells (ProB cells) into precursor B cells (PreB cells) is dictated by immunoglobulin heavy chain checkpoint (IgHCC), where the IgHC encoded by a productively rearranged
Indexed as
AllelesAnimalsBiomarkersB-LymphocytesGenetic LociImmunoglobulin Heavy ChainsMice, Inbred C57BLPrecursor Cells, B-LymphoidReproducibility of ResultsRNA, MessengerBiomarkersImmunoglobulin Heavy ChainsRNA, Messengerallelic exclusionearly B cell developmentIg heavy chain checkpointPreB cell antigen receptorread-through translation
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Ig heavy chain protein but not its message controls early B cell development. · full record | OpenQuestion